Imagine a future where we can tackle rare and devastating liver diseases with innovative treatments. Yaqrit, a clinical-stage company, is taking on this challenge with their advanced microbiome therapeutic, YAQ001, also known as Carbalive. This treatment is designed to target primary sclerosing cholangitis (PSC), a progressive liver disease that affects the bile ducts and can lead to liver failure. But here's where it gets controversial: PSC often goes hand in hand with inflammatory bowel disease (IBD), a condition that wreaks havoc on the gut. And this is the part most people miss - there are currently no approved treatments for PSC, leaving patients with limited options.
Yaqrit's YAQ001 offers a glimmer of hope. It's an oral microbiome treatment that aims to address the toxicities and inflammation associated with advanced liver disease. But what sets it apart? Well, it's a nanoporous carbon bead adsorbent that stays in the gut and doesn't get absorbed by the body. This unique design allows it to adsorb both large and small toxins and inflammatory molecules, reducing their harmful effects.
The treatment has already shown promising results in patients with liver cirrhosis, and now Yaqrit is taking it a step further with a proof-of-concept study in PSC patients. The study, coordinated by researchers at the Queen Elizabeth Hospital, Birmingham, is supported by a generous funding grant from LifeArc.
"PSC is a progressive condition with no approved treatments. LifeArc's funding has been instrumental in bringing hope to patients and their families," said Professor Palak Trivedi, the study's Principal Investigator.
Yaqrit's CEO, Troels Jordansen, emphasizes the company's focus on late-stage liver disease treatment: "YAQ001 addresses common issues in advanced liver disease while also showing potential for a broader spectrum of conditions."
The study's data, expected in the second half of 2026, will provide valuable insights into the safety and dose-escalation of YAQ001 in PSC-IBD patients. Yaqrit is also preparing for pivotal European trials in decompensated cirrhosis and irritable bowel syndrome (IBS) to obtain a CE Mark for YAQ001, classified as a medical device in Europe.
Professor Rajiv Jalan, Yaqrit's Founder and Chief Medical Officer, is optimistic: "The data from the cirrhosis study is highly encouraging, and this latest trial will further our understanding of YAQ001's potential."
Yaqrit's earlier clinical study, presented at the 2025 EASL Congress, confirmed that YAQ001 is safe for cirrhosis patients and reduces systemic inflammation and gut permeability. By creating a healthier gut environment, YAQ001 encourages the growth of beneficial microbes and reduces the abundance of harmful ones. It also positively impacts the microbes' virulence and their resistance to antibiotics.
So, is YAQ001 the game-changer we've been waiting for in the treatment of PSC and IBD? What are your thoughts on the potential of microbiome therapeutics? We'd love to hear your opinions in the comments below!
